UFP-512
UFP-512 has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Oct 23, 2025: “Delta-opioid receptor ameliorates microglia-induced synapse loss by regulating C1q in Alzheimer disease pathology”.
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Changzhou Science and Technology Bureau and 3 more
- Animals1
What did studies of UFP-512 find?
4Studies of UFP-512 measured 4 outcomes, among them cognitive function, synaptic protein loss and complement system.
Cognitive function
upin mice1
1 study
Cognitive function
upin mice1
UFP-512 improves cognitive function in mice (APP/PS1 mice).
“consequently improved cognitive performance of these Alzheimer's disease (AD) mice”
AnimalsAPP/PS1 mice
Brain, behavior, and immunity
Synaptic protein loss
downin mice1
1 study
Synaptic protein loss
downin mice1
UFP-512 prevents synaptic protein loss in mice (APP/PS1 mice).
“prevented synaptic protein loss”
AnimalsAPP/PS1 mice
Brain, behavior, and immunity
Complement system
downin mice1
1 study
Complement system
downin mice1
UFP-512 inhibits complement system in mice (DOR-C1q interaction in UFP-512-treated APP/PS1 mice).
“This interaction subsequently suppressed CCP activation”
AnimalsDOR-C1q interaction in UFP-512-treated APP/PS1 mice
Brain, behavior, and immunity
C1q
downin mice1
1 study
C1q
downin mice1
UFP-512 decreases C1q in mice (APP/PS1 transgenic mice).
“Activating DOR with the specific agonist UFP-512 in aged APP/PS1 mice reduced cerebral C1q levels”
AnimalsAPP/PS1 transgenic micebrain
Brain, behavior, and immunity